Patents Represented by Attorney, Agent or Law Firm Hana Verny
-
Patent number: 7427633Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: April 2, 2007Date of Patent: September 23, 2008Assignee: Gilead Sciences, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 6982091Abstract: Devices, methods, and compositions for cancer therapy by administration of chemotherapeutic agents and/or inhibitors of membrane efflux systems to the vagina for topical and systemic tumor targets.Type: GrantFiled: August 21, 2002Date of Patent: January 3, 2006Assignee: UMD, Inc.Inventors: Giovanni M. Pauletti, James H. Liu, Leslie Z. Benet, Wolfgang A. Ritschel
-
Patent number: 6949252Abstract: The present invention relates to compositions and methods for preparing tissues or tissue constructs. In selected embodiments, the invention relates to the construction of a multi-layered biological structure (i.e. system) that includes a cellular support matrix seeded with living cells derived from a native tissue. The present invention also relates to tissue culture protocols to promote the in vitro growth of tissues and tissue constructs.Type: GrantFiled: March 22, 2002Date of Patent: September 27, 2005Assignee: Histogenics, Corp.Inventors: Shuichi Mizuno, Toshimasa Tokuno, Laurence J. Berlowitz Tarrant
-
Patent number: 6905701Abstract: Devices, methods, and improved formulation for transmucosal vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the systemic circulation using a vaginal device comprising an improved bisphosphonate formulation for transmucosal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transmucosal delivery of bisphosphonates to the general circulation.Type: GrantFiled: January 22, 2003Date of Patent: June 14, 2005Assignee: UMD, Inc.Inventors: Giovanni M. Pauletti, Chris E. Clendening
-
Patent number: 6780818Abstract: The present invention concerns a quantitative organic vapor-particle sampler which can efficiently sample both semi-volatile organic gases and particulate components through the use of a unique sorbent resin coating and process. The sampler of the present invention comprises in its broadest aspect a tubular device having an inlet at one end through which organic vapor/particles are introduced, an outlet at the other end through which gases exit, at least one annular denuder interposed there between which is coated on the inside surface of the annulus with a specially prepared resin absorbent, which selectively absorbs organic vapors contained in the gases introduced into the inlet, and a filter which traps and collects particles.Type: GrantFiled: April 10, 2001Date of Patent: August 24, 2004Assignee: The Regents of the University of CaliforniaInventors: Lara Gundel, Joan M. Daisey, Robert K. Stevens
-
Cryptopain antibodies for prophylaxis, treatment, diagnosis and detection of Cryptosporidium species
Patent number: 6759044Abstract: Vaccines, antibodies, proteins, DNAs and RNAs for diagnosis, prophylaxis, treatment and detection of Cryptosporidium species or Cryptosporidium species infections. Cryptosporidium species antigen and DNAs and RNA encoding the Cryptosporidium antigen and fragments thereof and recombinant proteins or fusion proteins produced thereby. Methods for diagnosis, prophylaxis, treatment and detection of Cryptosporidium species infections.Type: GrantFiled: June 20, 2000Date of Patent: July 6, 2004Assignee: The Regents of the University of CaliforniaInventors: Carolyn Petersen, Jin-Xing Huang -
Patent number: 6753154Abstract: A human AZU-1 gene, mutants, variants and fragments thereof. Protein products encoded by the AZU-1 gene and homologs encoded by the variants of AZU-1 gene acting as tumor suppressors or markers of malignancy progression and tumorigenicity reversion. Identification, isolation and characterization of AZU-1 and AZU-2 genes localized to a tumor suppressive locus at chromosome 10q26, highly expressed in nonmalignant and premalignant cells derived from a human breast tumor progression model. A recombinant full length protein sequences encoded by the AZU-1 gene and nucleotide sequences of AZU-1 and AZU-2 genes and variant and fragments thereof. Monoclonal or polyclonal antibodies specific to AZU-1, AZU-2 encoded protein and to AZU-1, or AZU-2 encoded protein homologs.Type: GrantFiled: June 25, 1999Date of Patent: June 22, 2004Assignee: The Regents of the University of CaliforniaInventors: Huei-Mei Chen, Mina Bissell
-
Patent number: 6716596Abstract: Novel agents acting as co-factors for replacement of NAD(P)+/NAD(P)H co-enzyme systems in enzymatic oxido-reductive reactions. Agents mimicking the action of NAD(P)+/NAD(P)H system in enzymatic oxidation/reduction of substrates into reduced or oxidized products. A method for selection and preparation of the mimicking agents for replacement of NAD(P)+/NAD(P)H system and a device comprising co-factors for replacement of NAD(P)+/NAD(P)H system.Type: GrantFiled: March 12, 2001Date of Patent: April 6, 2004Assignee: The Regents of the University of CaliforniaInventors: Richard H. Fish, John B. Kerr, Christine H. Lo
-
Patent number: 6660249Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.Type: GrantFiled: December 20, 2001Date of Patent: December 9, 2003Assignee: Salus Pharma, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 6594947Abstract: A three-dimensional collapsible multi-component device and assembly. The device comprises a mountable housing for mounting under a shelf, or a wall or the like in an unobtrusive or discreet manner. The housing has a first flat configuration for transportation and storage and a second three-dimensional configuration for device deployment. The device housing further includes an insert having an adhesive surface and a dispenser comprising pheromone, kairomone or other attractant, lure or bait, or, alternatively, a repellant or a combination of any of these. The adhesive is effective for trapping multiple orders of insects. A plurality of attractants, etc., is simultaneously used for attracting multiple orders of insects. The insert is selectable, removable and replaceable.Type: GrantFiled: October 17, 2001Date of Patent: July 22, 2003Assignee: Trece, Inc.Inventors: Bill W. Lingren, Don H. Lenker
-
Patent number: 6582700Abstract: The present invention concerns a synthetic construct comprising a linear core chain having two or more side chains pending directly from different points on the linear core chain. Each of the side chains comprises an epitopic site of an antigen or a peptide. The synthetic constructs are monomeric units that can be linked together or polymerized to form a polymer. In this embodiment the epitopic sites of the side chains may be the same or different. The linear core chain may be a linear sequence of amino acids having two or more of the same peptide pending directly from different points on the linear sequence. Another aspect of the present invention concerns a support having one or more of the above synthetic constructs or polymers coupled thereto. Another embodiment of the present invention is directed to antibodies raised against the above synthetic constructs or polymers. The antibodies can be purified using the above mentioned supports.Type: GrantFiled: November 13, 1998Date of Patent: June 24, 2003Assignee: Medical University of South CarolinaInventor: Christian Schwabe
-
Patent number: 6572849Abstract: Self-preserved nasal, inhalable and topical ophthalmic preparations and medications which destroy, inhibit or therapeutically significantly limit microbial growth within said preparations or medications. The nasal, inhalable, and topical ophthalmic preparations and medications are mildly buffered and maintain a stable pH at pH 3.5 or lower.Type: GrantFiled: September 20, 2001Date of Patent: June 3, 2003Inventor: Lee Shahinian, Jr.
-
Patent number: 6572874Abstract: Devices, methods, and compositions for vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the vagina using a medicated intravaginal device comprising a bisphosphonate composition formulated for transvaginal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transvaginal delivery of bisphosphonates to the general circulation.Type: GrantFiled: July 27, 2000Date of Patent: June 3, 2003Assignee: UMD, Inc.Inventors: Donald C. Harrison, James H. Liu, Giovanni M. Pauletti, Wolfgang A. Ritschel
-
Patent number: 6566354Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.Type: GrantFiled: October 5, 2001Date of Patent: May 20, 2003Assignee: Kaneka CorporationInventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
-
Patent number: 6552103Abstract: Novel biomimetic hydrogel materials and methods for their preparation. Hydrogels containing acrylamide-functionalized carbohydrate, sulfoxide, sulfide or sulfone copolymerized with a hydrophilic or hydrophobic copolymerizing material selected from the group consisting of an acrylamide, methacrylamide, acrylate, methacrylate, vinyl and a derivative thereof present in concentration from about 1 to about 99 wt %. and methods for their preparation. The method of use of the new hydrogels for fabrication of soft contact lenses and biomedical implants.Type: GrantFiled: May 19, 2000Date of Patent: April 22, 2003Assignee: The Regents of the University of CaliforniaInventors: Carolyn Bertozzi, Ravindranath Mukkamala, Oing Chen, Hopin Hu, Dominique Baude
-
Patent number: 6528052Abstract: A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied hydrostatic pressure followed and interrupted by periods of recovery. The application of the intermittent hydrostatic pressure at physiological levels 5-10 MPA for an interval of 4 hours followed by a recovery period up to about 20 hours, said pressure applied to the cartilage cells in vitro, explants of cartilage ex vivo and in vivo to cartilage that remains intact within te joint space of diarthrotic joints.Type: GrantFiled: September 29, 2000Date of Patent: March 4, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: R. Lane Smith, Dennis R. Carter, David J. Schurman
-
Patent number: 6528049Abstract: Novel bisexual attractants for lepidopterous insect pests isolated from pears or apples. A method for monitoring and control of codling moth and other species of Lepidoptera comprising a lure and kill, mating disruption or mass trapping strategy. A method of using a formulation containing the bisexual attractants with or without an insecticide and/or pheromone for control of the insect pests.Type: GrantFiled: April 23, 2001Date of Patent: March 4, 2003Assignees: Trece, Inc., The United States of America as represented by the Secretary of AgricultureInventors: Douglas M. Light, Clive A. Henrick
-
Patent number: 6516558Abstract: A three-dimensional collapsible insect trap and assembly for capturing and monitoring insects comprising a collapsible carton container coated externally and internally. The carton container, collapsed for shipping and storing, is easily assembled into a three-dimensional trap. The trap comprises essentially a carton container suited to be assembled into a three-dimensional trap, a locking clasp and, optionally, an attachment means for attaching the trap to a place of insect infestation monitoring.Type: GrantFiled: May 17, 2000Date of Patent: February 11, 2003Assignee: Trece, Inc.Inventors: Bill W. Lingren, Don H. Lenker
-
Patent number: 6514697Abstract: Cryptosporidium GP900, P68 and cryptopain antigens, antibodies, DNA or RNA for detection of Cryptosporidium in biological and environmental samples. A method for diagnosis of cryptosporidiosis. Kits and assays for the detection of Cryptosporidium comprising antigens, antibody, DNA or RNA components for immunological detection of Cryptosporidium protein with antibody, or detection of Cryptosporidium DNA by PCR amplification with GP900, P68 or cryptopain primers and probes for hybridization.Type: GrantFiled: June 6, 2000Date of Patent: February 4, 2003Assignee: The Regents of the University of CaliforniaInventors: Carolyn Petersen, Debra A. Barnes, Richard C. Nelson, Jiri Gut
-
Patent number: 6516294Abstract: The nuclear receptor for the steroid hormone 1&agr;,25-dihydroxyvitamin D3, its ligand binding domain, three-dimensional model thereof and a method for selection of suitable vitamin D3 binding to the 1&agr;,25-dihydroxyvitamin D3 receptor. A three-dimensional model for residues 142-427 of the ligand binding domain of the human nuclear receptor for 1&agr;,25-dihydroxyvitamin D3 used to identify the interaction of the conformationally flexible natural hormone 1&agr;,25(OH)2D3 and a number of related analogs with the receptor ligand binding domain. A method for identification and generation of new potential analog drug forms of dihydroxyvitamin D3.Type: GrantFiled: July 1, 1999Date of Patent: February 4, 2003Assignee: The Regents of the University of CaliforniaInventor: Anythony W. Norman